pharmaphorum

JANUARY 13, 2023

The ‘big three’ insulin producers Novo Nordisk, Eli Lilly, and Sanofi are being sued by the state of California for allegedly working together to set artificially inflated prices for their products. The suit follows legal action over insulin pricing taken by other states, including Arkansas , Kansas, Mississippi, and Minnesota.

Insulin 105

Insulin Manufacturing Production Pharmacy 105

XTalks

FEBRUARY 8, 2024

The top 15 diabetes drugs in 2023, according to 2022 sales data, reflect the current state of diabetes management and hint at the evolving needs and trends within this critical area of healthcare. Read on to learn more about the top 15 diabetes drugs in 2023, based on 2022 sales statistics. mL subcutaneous solution (2 mg/1.5

Sales 52

Sales Insulin FDA Approval Drugs 52

pharmaphorum

NOVEMBER 11, 2022

In addition to the financial hit, the stunt has only served to draw attention to Lilly’s role in the insulin pricing crisis in the United States, where multiple patients have died because of rationing unaffordable insulin. That’s why other insulin stocks are falling too. Happy Disability Awareness Month.

Insulin 98

Insulin Branding Production Marketing 98

Fierce Pharma

MARCH 14, 2024

Biocon and Eris have expanded a previous agreement, with Biocon selling Indian branded formulations businesses to Mumbai-based Eris for $150M.

Branding 90

Branding Insulin Sales 90

pharmaphorum

JULY 14, 2021

Eli Lilly bought a stake in Protomer Technologies and its glucose-sensing insulin platform last year, and it must like what it has seen in the programme since then – it has just agreed to buy the company outright. . It was also responsible for the first recombinant insulin product – Humulin – which launched in 1982 and remains on sale.

Insulin 98

Insulin Protein Production Sales 98

pharmaphorum

JULY 29, 2021

Generic drugmaker Mylan has become the first company to secure FDA approval for a biosimilar product that is considered completely interchangeable with the reference product – namely Sanofi’s once-daily insulin Lantus. Biosimilars marketed in the US typically have list prices 15% to 35% lower than their reference products at launch.

Insulin 98

Insulin Drugs Production Generic Drugs 98

pharmaphorum

NOVEMBER 26, 2021

Novo Nordisk has said that the introduction of value-based procurement (VBP) for insulin products by the Chinese government will have an impact on its revenues next year. The VBP for insulin – which applies to supplies destined for hospitals in China – is expected to be implemented during the first half of 2022, according to Novo Nordisk.

Insulin 59

Insulin Production Sales Marketing 59

XTalks

MARCH 26, 2021

In Episode 1 of the Xtalks Life Science Podcast, Sarah discusses a new condition called “Mask-Associated Dry Eye” and Ayesha talks about Droplet Micron, an innovative insulin needle. Read the full articles here: Why Mask-Associated Dry Eye Won’t Necessarily Boost Restasis Sales.

Life Science 76

Life Science Insulin Sales Marketing 76

Pharmaceutical Technology

APRIL 25, 2023

Amphastar is expected to make up to $450m in milestone payments based on sales of Baqsimi. Lilly launched the drug in 2019 to provide rescue treatment for diabetes patients who take insulin. in global sales reported last year. It is now available in 27 international markets, with $139.3m

Insulin 130

Insulin Drugs Sales Marketing 130

Pharmaceutical Technology

APRIL 10, 2023

Furthermore, Galvus can be used in combination with other medicinal products such as insulin when unable to offer adequate glycaemic control. With reported sales of $32.7m (Rs2.68bn), Galvus is anticipated to boost Cipla’s portfolio in the diabetes care segment.

Branding 130

Branding Insulin Drugs Production 130

STAT News

NOVEMBER 17, 2022

The decision is a partial win for AbbVie, since its rheumatoid arthritis treatment has generated almost $200 billion in sales in nearly two decades. … UnitedHealth Group’s pharmacy benefits manager, OptumRx, will keep AbbVie’s Humira alongside up to three biosimilar medicines next year, Bloomberg News writes.

Insulin 96

Insulin Pharmacy Sales Medicine 96

pharmaphorum

AUGUST 6, 2020

Novo said that COVID-19 has begun to affect sales, with fewer new starts as a result of social distancing measures. The company’s diabetes care products saw an increase in sales during the second quarter, although this was offset by lower sales of insulin. This was on sales that were flat at 30 billion DKK ($4.77

Insulin 52

Insulin Sales Production Drugs 52

Delveinsight

AUGUST 18, 2021

In Type 2 diabetes, the body cells become resistant to insulin. The pancreas produces insulin that helps glucose get into cells to be used for energy. Due to Type 2 diabetes, either the body doesn’t make enough insulin or it doesn’t use insulin properly as a result the blood glucose or blood sugar gets too high.

Insulin 94

Insulin Marketing Development Big Data 94

Pharmaceutical Technology

MARCH 29, 2023

Under the terms of the deal, the company will receive an upfront payment of $50m, along with undisclosed licence and performance milestone payments, and tiered royalties on product sales. Evotec noted that the total transaction results in a $4bn deal, including the upfront and downstream performance milestone payments.

Clinical Trials 130

Clinical Trials Clinical Trials Insulin Medicine 130

Drug Channels

MARCH 30, 2023

Humira sales would be decline by about 37% in 2023—which is at the lower end of its previous erosion projection of 35% to 55%. Its strategy echoes the pricing of the first interchangeable insulin biosimilars— as I predicted in 2021. In February, AbbVie stated that U.S. Much more to come.

Insulin 85

Insulin Pharmacy Drugs Sales 85

pharmaphorum

JANUARY 28, 2021

One of these markets is the insulin market. Up until now, the insulin market has experienced little competition and, as a result, prices have soared over the years. Currently, more than seven million patients rely on insulin, and that number is growing each year. But, that will soon be changing, due to biosimilars.

Marketing 104

Marketing Insulin HR Production 104

pharmaphorum

NOVEMBER 15, 2022

It seems Lilly might have cut Twitter some slack if it had responded promptly to its frantic attempts to get the post – put up by someone who paid $8 to verify the imposter @EliLillyandCo account – which claimed that “insulin is free now.”

Insulin 87

Insulin Branding Sales Marketing 87

XTalks

NOVEMBER 3, 2022

Mounjaro has thus taken off stronger than expected, surpassing Wall Street sales forecasts during the third quarter. Mounjaro was approved this summer as a Type 2 diabetes treatment and is the first diabetes drug with dual action, targeting two hormones involved in insulin production and appetite (GIP and GLP-1).

Sales 98

Sales FDA Approval Production Insulin 98

pharmaphorum

MAY 21, 2021

In SURPASS-4 – the last of Lilly’s registration studies for the dual GLP-1/GIP agonist – tirzepatide met all its primary and secondary objectives, besting treatment with insulin glargine, a long-acting human insulin product that is a mainstay of diabetes treatment, in diabetics with increased cardiovascular risk.

Trials 52

Trials Insulin Sales Drug Delivery 52

pharmaphorum

NOVEMBER 21, 2022

The company argues that the cost is justified as Tzield (teplizumab) is the first drug that can delay the onset of type 1 diabetes, fending off the time when they become highly reliant on insulins and at risk of the serious complications that can accompany advanced T1D.

Drugs 116

Drugs Insulin FDA Approval Sales 116

pharmaphorum

JULY 7, 2021

Three months ago, the FDA said it was unconvinced by a bridging study designed to show equivalence between Provention’s product intended for commercial sale, made by contract manufacturer AGC Biologics, and the drug that teplizumab’s original developer Eli Lilly used in clinical trials.

Drugs 98

Drugs Insulin Contract Manufacturing Antibody 98

Pharmaceutical Technology

DECEMBER 22, 2022

The category crosses over with many of our other categories and can include new products, novel product features, new business practices, new marketing and sales strategies and more. The category includes any projects that demonstrate an innovative approach to the market. Civica JAAQ Sanofi. appeared first on Pharmaceutical Technology.

Insulin 130

Insulin Production Development Genetics 130

pharmaphorum

JANUARY 6, 2023

With the US economy teetering on a recession, sales and marketing budgets are expected to take a hit among businesses across sectors. On 14th November 2022, Eli Lilly apparently wrote on its Twitter account, “We are excited to announce insulin is free now.” The pharmaceutical industry is no exception. Industry frustrations.

Manufacturing 105

Manufacturing Sales Insulin Drugs 105

pharmaphorum

FEBRUARY 18, 2021

The history of insulin captures one of the mystifying complexities of the pharmaceutical market — how long-standing drugs become more expensive with time and competition fails to hold down prices. 6 The stakes were extremely high, with annual costs of insulin reaching $736 per patient in 2013, up threefold since 2002. billion in 2004.14

Branding 52

Branding Insulin Sales FDA Approval 52

Drug Channels

SEPTEMBER 7, 2022

In the video below, I review these developments and discuss lessons from the launch of Semglee, the first interchangeable insulin. In many therapeutic areas, biosimilars’ market share is approaching 80%. I also offer some thoughts on 2023 and 2024. That’s when Humira, the best-selling drug in the U.S.,

Insulin 85

Insulin Drugs Marketing Development 85

Pharmaceutical Technology

JUNE 29, 2022

In 2021, Novo Nordisk Pharmatech, a leading pharmaceutical-grade insulin and Quats product supplier announced plans to enter the enzyme market. The enzymes must be manufactured under cGMP conditions – completely free of animal-derived ingredients.”. Developing best-in-class speciality enzymes.

Drugs 295

Drugs Gene Therapy Manufacturing Production 295

Roots Analysis

NOVEMBER 27, 2023

Expanding Production Capacity The Chartres facility, which initially received a EUR 130 million investment earlier this year, plays a crucial role in Novo Nordisk’s production of pre-filled injector pens and insulin. With this additional EUR 2.1 billion and USD 3 billion, respectively, in the first nine months of the year.

Manufacturing 40

Manufacturing Sales Production Marketing 40

The Pharma Data

APRIL 24, 2023

Amphastar expects to provide dedicated commercial investment for BAQSIMI with the goal of enabling more people on insulin to be prepared with a glucagon rescue treatment for severe hypoglycemia. Worldwide sales for BAQSIMI totaled $139.3 million in 2022. Jack Zhang, Ph.D.,

Insulin 40

Insulin Medicine Production Clinical Trials 40

pharmaphorum

MARCH 21, 2022

Teplizumab is thought to work by binding to CD3, preventing the activation of T cells that attack and kill insulin-producing pancreatic beta cells in the autoimmune disease. In the latter, teplizumab wasn’t able to show an impact on insulin use or HbA1c, an indirect measure of glucose control over time.

Drugs 52

Drugs Insulin Contract Manufacturing Clinical Trials 52

Drug Discovery World

MARCH 6, 2023

Biopharmaceutical subsidiary Rhythm Pharmaceuticals Netherlands has acquired Xinvento, a Netherlands-based biotech company focused on developing therapies for congenital hyperinsulinism (CHI). The post Rhythm Pharmaceuticals buys biotech focused on rare disease appeared first on Drug Discovery World (DDW).

Genetic Disease 52

Genetic Disease Insulin Genetics Sales 52

The Pharma Data

MAY 13, 2021

The insulin-like effect of muscle contraction. Exercise and insulin sensitivity: a review. AMPK and Exercise: Glucose Uptake and Insulin Sensitivity. The insulin-like effect of muscle contraction. Exercise and insulin sensitivity: a review. AMPK and Exercise: Glucose Uptake and Insulin Sensitivity.

Insulin 52

Insulin Production Protein Sales 52

pharmaphorum

NOVEMBER 18, 2022

” T1D occurs when the immune system attacks and destroys the insulin-producing pancreatic beta cells that make insulin, and occurs in three stages. In stage 1 there are antibodies against the beta calls, but blood glucose levels remain normal and there are no symptoms.

Drugs 52

Drugs FDA Approval Insulin Clinical Trials 52

pharmaphorum

FEBRUARY 28, 2022

Biocon’s partnership with Mylan – which merged with Pfizer’s Upjohn to form Viatris in 2020 – dates back more than a decade and has generated a number of biosimilars including insulin analogues, antibodies and recombinant proteins.

Insulin 96

Insulin Production Marketing Engineer 96

pharmaphorum

JULY 1, 2022

In its favour too is that it does not work as a diabetes medicine like the SGLT2s, so patients on insulin do not need to adjust their dose if Kerendia is added in to their treatment.

Insulin 52

Insulin Sales Drugs Marketing 52

World of DTC Marketing

AUGUST 16, 2020

It suddenly wasn’t about patients as much as it was about ROI and sales. Today, pharma CEOs make tens of millions of dollars because of one goal: sales. When I first started in the industry DTC was fairly new as we launched a number of groundbreaking drugs such as statins. Slowly I saw a change within companies.

Sales 196

Sales Drugs Insulin Development 196

XTalks

FEBRUARY 8, 2021

Last year, Biocon Biologics and Mylan announced they’d be seeking interchangeable status for their long-acting insulin product Semglee , developed to be an alternative to Sanofi’s Lantus (insulin glargine). This includes information on approved indications and risk statements applicable to both the biosimilar and its reference product.

Production 78

Production Insulin Branding Generic Drugs 78

STAT News

DECEMBER 5, 2022

Horizon shares surged over the past week after the company said it is in separate preliminary talks with J&J, Amgen, and Sanofi about a possible sale. Janssen Global Services, J&J’s pharmaceutical division, did not provide a reason why it is not planning to proceed with an offer in a statement released Saturday.

Insulin 52

Insulin Manufacturing Medicine Drugs 52